SBR 759

Drug Profile

SBR 759

Alternative Names: Phosphate binder - Novartis; SBR-759; Seboren

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator SeBo GmbH
  • Developer Novartis
  • Class Disaccharides; Glucans; Iron compounds; Polymers
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperphosphataemia

Most Recent Events

  • 01 Dec 2013 Discontinued - Phase-II for Hyperphosphataemia in Japan and Taiwan (PO)
  • 31 Aug 2012 No development reported - Phase-III for Hyperphosphataemia in Japan (PO)
  • 31 Dec 2007 Phase-II clinical trials in Hyperphosphataemia in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top